|Articles|August 10, 2022
- Pharmaceutical Executive-08-01-2022
- Volume 42
- Issue 8
Pharmaceutical Executive, August 2022 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive August 2022 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 3 years ago
The Silver Lining Of Innovation in Genetic Medicineabout 3 years ago
Navigating the Financial Meltdown for Biopharmaabout 3 years ago
The Potential of Proteomicsabout 3 years ago
Getting ‘Personal’ With Vaccine Developmentabout 3 years ago
A World of Opportunityabout 3 years ago
Has Biotech Bottomed Out—and is Recent Recovery Sustainable?Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: FDA Approves Novo Nordisk's Rybelsus and Roche’s Gazyva/Gazyvaro
2
Merck Planning $70 Billion Investment for US Expansion
3
Amazon and WeightWatchers Partner for DTC Weight Loss Medication Offerings
4
FDA Approves Tezspire as First Biologic Targeting TSLP for Chronic Rhinosinusitis With Nasal Polyps
5
